| Verifiedfields | changed |
|---|---|
| Watchedfields | changed |
| Verifiedrevid | 460025906 |
| Source | zu/o |
| Target | TNF alpha |
| Tradename | Cimzia |
| Medlineplus | a608041 |
| Dailymedid | Certolizumab pegol |
| Pregnancy au | C |
| Routes of administration | Subcutaneous |
| Atc prefix | L04 |
| Atc suffix | AB05 |
| Legal au | S4 |
| Legal us | Rx-only |
| Legal us comment | [1] |
| Legal eu | Rx-only |
| Legal eu comment | [2] |
| Elimination half-life | about 11 days |
| Excretion | Kidney (PEG only) |
| Cas number | 428863-50-7 |
| Drugbank | DB08904 |
| Chemspiderid | none |
| Unii | UMD07X179E |
| Kegg | D03441 |
| Chembl | 1201831 |
| Synonyms | CDP870 |
| C | 2115 |
| H | 3252 |
| N | 556 |
| O | 673 |
| S | 16 |
Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease,[3][4] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.[5][6][1]
Certolizumab pegol is a therapeutic alternative on the World Health Organization's List of Essential Medicines.[7]
Medical uses
- Crohn's Disease
- On April 22, 2008, the U.S. Food and Drug Administration (FDA) approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.[6][8][9]
- Rheumatoid arthritis
- On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA in October 2009.[2]
- Psoriatic arthritis
- On September 27, 2013, the U.S. FDA approved Cimzia for the treatment of adult patients with active psoriatic arthritis.[10]
Method of action
Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.[11]
Clinical trials
- Crohn's disease
- Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease.[3][11][12][13]
- Axial spondyloarthritis
- In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis.[14]
- Rheumatoid arthritis
- Certolizumab appears beneficial in those with rheumatoid arthritis.[15]
References
- ^ "Cimzia- certolizumab pegol kit Cimzia- certolizumab pegol injection, solution". DailyMed. April 24, 2020. Retrieved July 18, 2020.
- ^ "Cimzia EPAR". European Medicines Agency. October 22, 2009. Archived November 9, 2009 at the Wayback Machine. Retrieved November 15, 2009.
- ^ Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S (July 2007). "Certolizumab pegol for the treatment of Crohn's disease". The New England Journal of Medicine. 357 (3): 228–238. doi:10.1056/NEJMoa067594. PMC 3187683. PMID 17634458
- ^ Goel N, Stephens S (2010). "Certolizumab pegol". mAbs. 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560
- ^ Kaushik VV, Moots RJ (April 2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert Opinion on Biological Therapy. 5 (4): 601–606. doi:10.1517/14712598.5.4.601. PMID 15934837. S2CID 21974683
- ^ "Drug Approval Package: Cimzia (Certolizumab Pegol) NDA #125160". U.S. Food and Drug Administration (FDA). December 24, 1999. Archived February 15, 2015 at the Wayback Machine. Retrieved July 18, 2020.
- ^ The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474. hdl:10665/382243
- ^ "Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease". UCB press release. Archived February 18, 2012 at the Wayback Machine. Retrieved April 22, 2008.
- ^ Waknine Y (May 1, 2008). "FDA Approvals: Patanase, Actonel, Cimzia". Medscape. Retrieved May 1, 2008.
- ^ "Cimzia (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis". Archived October 1, 2013 at the Wayback Machine. Retrieved October 1, 2013.
- ^ Schreiber S, Khaliq-Kareemi M, Lawrance I, Hanauer S, McColm J, Bloomfield R, Sandborn W (2005). "Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (precise)". Gut. 54 (suppl 7): A82.
- ^ Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, McColm JA, Innes A, Schreiber S (2006). "Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECiSE 1)". Gastroenterology. 130 (4): A107.
- ^ "New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease". UCB. October 23, 2006. Archived March 29, 2020 at the Wayback Machine. Retrieved November 15, 2009.
- ^ Sieper J, Tubergen A, Coteur G, Woltering F, Landewe R (May 2013). "PMS50 – Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study". Value in Health. 16 (3): A227. doi:10.1016/j.jval.2013.03.1150
- ^ Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA (September 2017). "Certolizumab pegol (CDP870) for rheumatoid arthritis in adults". The Cochrane Database of Systematic Reviews. 2017 (9). doi:10.1002/14651858.CD007649.pub4. PMC 6483724. PMID 28884785